Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

  • Marco Falcone
    Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Giusy Tiseo
    Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Alessandro Leonildi
    Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Leonardo Della Sala
    Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Alessandra Vecchione
    Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Simona Barnini
    Microbiology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Alessio Farcomeni
    Department of Economics and Finance, University of Rome “Tor Vergata,” Rome, Italy
  • Francesco Menichetti
    Department of Clinical and Experimental Medicine, University of Pisa, Infectious Diseases Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

抄録

<jats:p> Cefiderocol may represent a therapeutic option for carbapenem-resistant <jats:named-content content-type="genus-species">Acinetobacter baumannii</jats:named-content> (CRAB) infections, but clinical data are limited. This is an observational retrospective study conducted in the University Hospital of Pisa including consecutive patients with CRAB infections (January 2020 to August 2021). </jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ